loading page

Sustained impact of subcutaneous immunotherapy among patients with allergic rhinitis who experienced treatment delay due to the COVID-19 pandemic: A multicenter, two-arm, real-world study
  • +10
  • SUIZI ZHOU,
  • Yibin Liu,
  • Jianrong Xue,
  • Juan Tang,
  • Qingqing Yu,
  • Shenhong Qu,
  • Shaojie Zhang,
  • Binyu Mo,
  • Jihui Li,
  • Yinhong Liu,
  • Yueying Yang,
  • De Yun Wang,
  • Qianhui Qiu
SUIZI ZHOU
Zhujiang Hospital, Southern Medical University
Author Profile
Yibin Liu
Zhujiang Hospital, Southern Medical University
Author Profile
Jianrong Xue
the Third People's Hospital of Changzhou
Author Profile
Juan Tang
First People's Hospital of Foshan
Author Profile
Qingqing Yu
First People's Hospital of Foshan
Author Profile
Shenhong Qu
People's Hospital of Guangxi Zhuang Autonomous Region
Author Profile
Shaojie Zhang
People's Hospital of Guangxi Zhuang Autonomous Region
Author Profile
Binyu Mo
Liuzhou people's Hospital
Author Profile
Jihui Li
Liuzhou people's Hospital
Author Profile
Yinhong Liu
Zhujiang Hospital, Southern Medical University
Author Profile
Yueying Yang
Zhujiang Hospital, Southern Medical University
Author Profile
De Yun Wang
Yong Loo Lin School of Medicine, National University of Singapore
Author Profile
Qianhui Qiu
Zhujiang Hospital, Southern Medical University, Guangzhou, China
Author Profile

Abstract

Background: The aim of this study is to investigate the impact of COVID-19 related treatment delay on subcutaneous immunotherapy (SCIT) efficacy in patients with allergic rhinitis (AR). Methods: The study was performed in 643 patients with SCIT appointments between February 1 and May 31, 2020. The clinical assessment, performed at baseline (V0) and one year later (V1), included visual analogue scale (VAS); daily symptom score (dSS); daily medication score (dMS); combined symptom and medication scores (CSMS); quality of life (QoL); self-rating anxiety scale (SAS); and self-rating depression scale (SDS) for each patient. Results: At V0, 249 patients were treated on schedule, and 394 were delayed (7 ± 4.68 weeks). Among them, 319 patients (105 on schedule, and 214 delayed) also completed the assessments at V1, with the absence of 25.39% patients due to completion of SCIT, and 25.35% patients were withdrawal. The results of all assessments were within the normal range for all patients at V0 and V1, with the exception of a slightly higher SDS score (56.13) at V0. In the SCIT delayed group. there was a significant positive correlation between the length (weeks) of the delay and SDS score, and this was significantly higher in patients with poor control of nasal symptoms. Conclusions: This study showed the long-term efficacy of SCIT for AR patients, including those who have had to delay normal therapy due to the COVID-19 outbreak. The psychological status of SCIT patients in response to lockdown of hospital services during this critical period should be considered.